Experience in the use of Bedakville in the therapy of multidrug-resistant tuberculosis and HIV infection.

Conclusions: The use of Bedaklivin in patients with a combination of tuberculosis and HIV infection increases the effectiveness of therapy to stop bacterial release in a shorter time to 2m months. The incidence of adverse reactions in this group of patients does not differ significantly from the control group.

Source: European Respiratory Journal - November 19, 2018 Category: Respiratory Medicine Authors: Chernokhaeva, I., Ershova, E., Pavlova, M., Starshinova, A., Sapozhnikova, N. Tags: Tuberculosis Source Type: research